Efficacy of Rebamipide Therapy in Aphthous Ulcers: A Prospective Study
Authors/Creators
- 1. MS-ENT, Senior Resident, Department of ENT, Chirayu Medical College, Bhopal, Madhya Pradesh, India
- 2. MS-ENT, MGM Medical College, Indore, Madhya Pradesh, India
- 3. MS-ENT, Gandhi Medical College, Bhopal, Madhya Pradesh, India
Description
Background: Recurrent aphthous stomatitis (RAS) poses a considerable challenge within the Otorhinolaryngology domain, impacting patients’ quality of life. Aim and Objectives: This prospective study aimed to assess the efficacy of Rebamipide therapy in managing RAS over 3 months. Methods: A cohort of 60 patients with recurrent aphthous ulcers was enrolled, receiving Rebamipide therapy orally in a Tertiary care center of Central India. Clinical evaluations, pain scores, and ulcer healing rates were recorded at baseline, 1 month, 2 months, and 3 months. Statistical analyses were conducted to assess changes over time. Results: Rebamipide therapy demonstrated a significant reduction in the frequency and severity of aphthous ulcers, with pain scores decreasing progressively over the 3-month period. Ulcer healing rates exhibited a consistent upward trend, reaching substantial levels by the study’s conclusion. Adverse events were minimal, with 5% of patients reported gastrointestinal discomfort. Conclusion: This study contributes evidence supporting Rebamipide as an effective and well-tolerated therapeutic option for RAS. Positive outcomes regarding reduced ulceration, improved pain scores, and enhanced ulcer healing rates underscore its potential clinical utility.
Abstract (English)
Background: Recurrent aphthous stomatitis (RAS) poses a considerable challenge within the Otorhinolaryngology domain, impacting patients’ quality of life. Aim and Objectives: This prospective study aimed to assess the efficacy of Rebamipide therapy in managing RAS over 3 months. Methods: A cohort of 60 patients with recurrent aphthous ulcers was enrolled, receiving Rebamipide therapy orally in a Tertiary care center of Central India. Clinical evaluations, pain scores, and ulcer healing rates were recorded at baseline, 1 month, 2 months, and 3 months. Statistical analyses were conducted to assess changes over time. Results: Rebamipide therapy demonstrated a significant reduction in the frequency and severity of aphthous ulcers, with pain scores decreasing progressively over the 3-month period. Ulcer healing rates exhibited a consistent upward trend, reaching substantial levels by the study’s conclusion. Adverse events were minimal, with 5% of patients reported gastrointestinal discomfort. Conclusion: This study contributes evidence supporting Rebamipide as an effective and well-tolerated therapeutic option for RAS. Positive outcomes regarding reduced ulceration, improved pain scores, and enhanced ulcer healing rates underscore its potential clinical utility.
Files
IJPCR,Vol16,Issue1,Article126.pdf
Files
(289.7 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:46f5c3cd03ed2188cd83e882d380d914
|
289.7 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-01-14
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue1,Article126.pdf
- Development Status
- Active
References
- 1. Preeti L, Magesh K, Rajkumar K, Karthik R. Recurrent aphthous stomatitis. J Oral Maxillofac Pathol. 2011 Sep;15(3):252-6. 2. Akintoye SO, Greenberg MS. Recurrent aphthous stomatitis. Dent Clin North Am. 2014 Apr;58(2):281-97. 3. Lee S, Jeong S, Kim W, Kim D, Yang Y, Yoon JH, Kim BJ, Min DS, Jung Y. Rebamipide induces the gastric mucosal protective factor, cyclooxygenase-2, via activation of 5'-AMP-activated protein kinase. Biochem Biophys Res Commun. 2017 Jan 29;483(1):449-455.4. Takagi T, Naito Y, Uchiyama K, Okuda T, Mizushima K, Suzuki T, Handa O, Ishikawa T, Yagi N, Kokura S, Ichikawa H, Yoshikawa T. Rebamipide promotes healing of colonic ulceration through enhanced epithelial restitution. World J Gastroenterol. 2011 Sep 7;17(33):380 2-9. 5. Kim YJ, Cheon JH, Lee SK, Kim JH, Lee YC. Rebamipide May Be Comparable to H2 Receptor Antagonist in Healing Iatrogenic Gastric Ulcers Created by Endoscopic Mucosal Resection: A Prospective Randomized Pilot Study. J Korean Med Sci. 2010 Apr;25(4):583-588. 6. Suzuki T, Konomi K, Mizue N, et al. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following infection with Helicobacter pylori. J Clin Biochem Nutr. 2011;48(1):103-110. 7. Nakamura N, Higuchi K, Takeuchi Y, et al. Inhibitory effects of rebamipide on oxidative stress in cultured guinea pig gastric mucosal cells. Dig Dis Sci. 2001;46(9):1967-1973. 8. Matsuda T, Ohno S, Hirohata S, et al. Efficacy of Rebamipide as Adjunctive Therapy in the Treatment of Recurrent Oral Aphthous Ulcers in Patients with Behçet's Disease. Drugs in R&D. 2003; 4:19–28.